Correspondence 0001493152-23-042022 from Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc.
Date: Nov. 20, 2023 · CIK: 0001716947 · Accession: 0001493152-23-042022
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275456
Letter
Ensysce Biosciences, Inc.
Ivanhoe Avenue, Suite 201
La Jolla, California 92037
November 20, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, NE
Washington, D.C. 20549
Attention: Jason Drory, Esq.
Re: Ensysce Biosciences, Inc.
Registration Statement on Form S-1
SEC File No. 333-275456
Filed November 9, 2023
Pre-Effective Amendment No. 1 filed November 17, 2023
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-275456) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 PM, Eastern Time, on November 21, 2023, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Eric D. Kline at (412) 454-5046 or Gregory Rubis at (609) 951-4105.
Please direct any questions or comments concerning this request to Eric Kline or Gregory Rubis.
ENSYSCE BIOSCIENCES, Inc.
By:
/s/ Lynn Kirkpatrick
Name: Dr. Lynn Kirkpatrick
Title: President and Chief Executive Officer
Cc:
Eric D. Kline, Troutman Pepper Hamilton Sanders LLP
Gregory Rubis, Troutman Pepper Hamilton Sanders LLP
Show Raw Text
CORRESP
1
filename1.htm
Ensysce
Biosciences, Inc.
7946
Ivanhoe Avenue, Suite 201
La
Jolla, California 92037
November
20, 2023
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, NE
Washington,
D.C. 20549
Attention:
Jason Drory, Esq.
Re:
Ensysce
Biosciences, Inc.
Registration
Statement on Form S-1
SEC
File No. 333-275456
Filed
November 9, 2023
Pre-Effective
Amendment No. 1 filed November 17, 2023
Ladies
and Gentlemen:
Pursuant
to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc.
(the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1
(File No. 333-275456) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement
will become effective at 4:00 PM, Eastern Time, on November 21, 2023, or as soon thereafter as is practicable, or at such other time
thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared
effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Eric D. Kline at (412)
454-5046 or Gregory Rubis at (609) 951-4105.
Please
direct any questions or comments concerning this request to Eric Kline or Gregory Rubis.
ENSYSCE
BIOSCIENCES, Inc.
By:
/s/
Lynn Kirkpatrick
Name:
Dr.
Lynn Kirkpatrick
Title:
President
and Chief Executive Officer
Cc:
Eric
D. Kline, Troutman Pepper Hamilton Sanders LLP
Gregory
Rubis, Troutman Pepper Hamilton Sanders LLP